Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)
Overview
This post-marketing surveillance study of CLAVAMOX® was designed to collect and assess the information on proper use, such as safety and efficacy, under actual use conditions, targeting pediatric Japanese patients with diseases (superficial skin infection, deep skin infection, lymphangitis, lymphadenitis, chronic pyoderma, pharyngitis, laryngitis, tonsillitis, acute bronchitis, cystitis, pyelonephritis) other than otitis media. ("CLAVAMOX" is a trademark of the GlaxoSmithKline group of companies.)
Full Title of Study: “Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2008
Interventions
- Drug: Amoxicillin and clavulanate
Arms, Groups and Cohorts
- Pediatrics patients prescribed amoxicillin and clavulanate
- Pediatrics patients prescribed amoxicillin and clavulanate for treatment of diseases other than otitis media during study period
Clinical Trial Outcome Measures
Primary Measures
- The number of incidence of adverse events in Japanese pediatric patients, with diseases other than otitis media, treated with amoxicillin and clavulanate based on prescribing information
- Time Frame: 2 months
- Clinical symptoms after treatment with amoxicillin and clavulanate
- Time Frame: 2 months
Participating in This Clinical Trial
Inclusion Criteria
- Pediatric subjects with diseases of superficial skin infection, deep skin infection, lymphangitis, lymphadenitis, chronic pyoderma, pharyngitis, laryngitis, tonsillitis, acute bronchitis, cystitis and pyelonephritis Exclusion Criteria:
- Not applicable
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 14 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- GlaxoSmithKline
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- GSK Clinical Trials, Study Director, GlaxoSmithKline
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.